JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

orphan drug act

The pricing controversy surrounding Duchenne muscular dystrophy (DMD) treatment

Posted: April 24, 2017

Categories: Reimbursements

Tags: orphan drug act, food and drug administration (fda), emflaza, duchenne muscular dystrophy, drug pricing, deflazacort

Author: Deirdre Cogan

The latest events surrounding the pricing of a Duchenne muscular dystrophy (DMD) treatment

Read more »